A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease [0.03%]
斜率模型与混合模型重复测量在阿尔茨海默病认知数据评估中比较的仿真研究
Yun-Fei Chen,Xiao Ni,Adam S Fleisher et al.
Yun-Fei Chen et al.
Introduction: In clinical trials of Alzheimer's disease, a mixed-model repeated measure approach often serves as the primary analysis when evaluating disease progression; a slope model may be secondary. ...
Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse [0.03%]
Posiphen对APP的翻译抑制作用：在APP/PS1小鼠中的有效性和药代动力学及药效学研究
Andrew F Teich,Ekta Sharma,Eliza Barnwell et al.
Andrew F Teich et al.
Introduction: Translational inhibition of amyloid precursor protein (APP) by Posiphen has been shown to reduce APP and its fragments in cell culture, animal models, and mildly cognitively impaired patients, making it a pr...
Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer's disease [0.03%]
生酮饮食干预阿尔茨海默病的可行性和有效性的数据
Matthew K Taylor,Debra K Sullivan,Jonathan D Mahnken et al.
Matthew K Taylor et al.
Introduction: We assessed the feasibility and cognitive effects of a ketogenic diet (KD) in participants with Alzheimer's disease. Methods: ...
Person-centered care for older people with dementia in the acute hospital [0.03%]
急性病医院的老年痴呆患者的以患者为中心的护理
Felicia Hui En Tay,Claire L Thompson,Chih Ming Nieh et al.
Felicia Hui En Tay et al.
Introduction: Patients with dementia (PWDs) are often subjected to enforced dependency and experience functional decline and emotional distress during hospital stay. Person-centered care (PCC) with specialized psychosocia...
Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease [0.03%]
小芝贝美拉明与单一使用小芝石南提取物治疗老年痴呆患者临床疗效的对照研究
Oliver Peters,Manuel Fuentes,Lisa Katharina Joachim et al.
Oliver Peters et al.
Introduction: Several studies have tested the N-methyl-D-aspartate-receptor antagonist memantine as an add-on to pre-existing treatment with acetylcholinesterase inhibitors. The objective of this study was to evaluate the...
Delayed-start analysis for demonstrating disease modification of solanezumab [0.03%]
延迟开始分析：索拉珠单抗可改变疾病进程的佐证
Frank J Wolters,M Arfan Ikram
Frank J Wolters
A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects [0.03%]
一项在健康志愿者中评估谷氨酰胺环化酶抑制剂PQ912的安全性与药代动力学的Ⅰ期研究
Inge Lues,Frank Weber,Antje Meyer et al.
Inge Lues et al.
Introduction: Pyroglutamate-amyloid-β (pE-Aβ) peptides are major components of Aβ-oligomers and Aβ-plaques, which are regarded as key culprits of Alzheimer's disease (AD) pathology. PQ912 is a competitive inhibitor of...
Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice [0.03%]
组蛋白去乙酰化酶6抑制剂（ACY-738）的药理学治疗可改善APP/PS1小鼠的阿尔茨海默病表型
Tabassum Majid,Deric Griffin,Zachary Criss nd et al.
Tabassum Majid et al.
Introduction: Current therapy for Alzheimer's disease (AD) focuses on delaying progression, illustrating the need for more effective therapeutic targets. Histone deacetylase 6 (HDAC6) modulates tubulin acetylation and has...
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab [0.03%]
轻中度阿尔茨海默病患者在巴尼单抗临床试验中的ADCS认知11项评分进展模型
Mahesh N Samtani,Steven X Xu,Alberto Russu et al.
Mahesh N Samtani et al.
Introduction: The objective of this study was to estimate longitudinal changes in disease progression (measured by Alzheimer's disease assessment scale-cognitive 11-item [ADAS-cog/11] scale) after bapineuzumab treatment a...
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials [0.03%]
基于巴尼鲁单抗试验痴呆评定残疾评分的阿尔茨海默病进展模型
Steven X Xu,Mahesh N Samtani,Alberto Russu et al.
Steven X Xu et al.
Objective: Disability assessment for dementia (DAD) measurements from two phase-3 studies of bapineuzumab in APOE ε4 noncarrier and carrier Alzheimer's disease (AD) patients were integrated to develop a disease progressi...